The Annual Meeting of the American Society of Clinical Oncology is the largest cancer meeting in the world. This year more than 33,000 oncologists and health care professionals were able to attend over 4000 oral and poster presentations on cutting edge cancer research. The theme of the 2007 meeting was “Translating research into practice”. Dr. Gabriel N. Hortobagyi, MD, the President of ASCO, noted in his Presidential Address that “ASCO members are uniquely positioned in the oncology research spectrum to implement the translation of basic research into clinical practice and accelerate the pace of progress at this level.”

Some of the most interesting and potentially practice-changing results were related to genitourinary tumors, including prostate and bladder cancer. We talked to some international leaders in urology at this year’s ASCO meeting to hear their impressions of these new data.

Treating localised prostate cancer - An interview with Professor W. J. Catalona at ASCO 2007

Professor Catalona reviewed the current status of active surveillance in the US, and the place of various treatments of localised prostate cancer. He also highlighted attempts to reduce the burden of hormone therapy on men with...

Professor W. J. Catalona

Impact of zoledronic acid on bone markers and survival - An interview with Dr. A. Lipton at ASCO 2007

There is evidence from a combined analysis of three randomised trials in different cancers that zoledronic acid has a positive impact on bone markers which may be associated with survival benefits.

 

Dr. A. Lipton

Update on renal cell carcinoma and bladder cancer from ASCO 2007 - An interview with Professor M. Wirth at ASCO 2007

Important and possibly practice-changing new data related to renal cell carcinoma and bladder carcinoma were presented at ASCO 2007. Professor Wirth gave his impressions of the results of some of these major trials.

 

Prof. M. Wirth

Promising new oral therapy for hormone-resistant prostate cancer - An interview with Professor M. Wirth at ASCO 2007

Patients with hormone-refractory prostate cancer who have failed chemotherapy currently have no treatment options. New data presented at ASCO 2007 show that oral satraplatin can significantly improve risk of disease progression...

Prof. M. Wirth

Emerging treatments for prostate cancer - An interview with Prof. K. Miller at ASCO 2007

At ASCO 2007 there were a number of presentations described new potential approaches to the treatment of prostate cancer. Prof. Miller reviewed some of the most interesting data.

 

Prof. K. Miller